Måndag 9 November | 14:02:31 Europe / Stockholm
Est. tid*
2026-10-20 - Kvartalsrapport 2026-Q3
2026-07-09 - Kvartalsrapport 2026-Q2
2026-05-06 - X-dag ordinarie utdelning GENT 0.60 NOK
2026-05-06 - Kvartalsrapport 2026-Q1
2026-05-05 - Årsstämma
2026-02-11 - Bokslutskommuniké 2025
2025-10-23 - Kvartalsrapport 2025-Q3
2025-07-10 - Kvartalsrapport 2025-Q2
2025-05-07 - X-dag ordinarie utdelning GENT 0.40 NOK
2025-05-07 - Kvartalsrapport 2025-Q1
2025-05-06 - Årsstämma
2025-02-12 - Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-04-30 - X-dag ordinarie utdelning GENT 0.00 NOK
2024-04-30 - Kvartalsrapport 2024-Q1
2024-04-29 - Årsstämma
2024-02-09 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning GENT 0.00 NOK
2023-05-05 - Kvartalsrapport 2023-Q1
2023-05-04 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning GENT 0.00 NOK
2022-05-18 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-10-21 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-05 - X-dag ordinarie utdelning GENT 0.00 NOK
2021-05-04 - Årsstämma
2021-04-16 - Kvartalsrapport 2021-Q1
2021-02-11 - Bokslutskommuniké 2020
2020-10-29 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-15 - X-dag ordinarie utdelning GENT 0.00 NOK
2020-05-14 - Årsstämma
2020-04-24 - Kvartalsrapport 2020-Q1
2020-02-14 - Bokslutskommuniké 2019
2019-11-21 - Extra Bolagsstämma 2019
2019-05-10 - X-dag ordinarie utdelning GENT 0.00 NOK
2018-07-13 - Extra Bolagsstämma 2018
2018-06-13 - X-dag ordinarie utdelning GENT 0.00 NOK
2018-02-27 - Bokslutskommuniké 2017
2017-06-06 - Årsstämma
LandNorge
ListaOslo Bors
SektorHälsovård
IndustriMedicinteknik
Gentian Diagnostics är ett medicinskt diagnostikbolag som utvecklar och tillverkar in vitro diagnostiska reagenser för högkapacitetsanalysatorer. Gentians expertis och fokus ligger inom homogena immunanalyser, speciellt infektioner, inflammationer, njursvikt och kongestiv hjärtsvikt. Bolagets huvudkontor och produktionsanläggningar finns i Moss, Norge, och betjänar den globala human- och veterinärdiagnostikmarknaden genom försäljnings- och representationskontor i ett antal nyckelländer.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Gentian Diagnostics - Grant of options

2026-11-06 10:27:32
Moss, 6 November 2026

Reference is made to the annual general meeting 6 May 2025 where guidelines for
remuneration of executive personnel were approved. In accordance with these
guidelines the board of Gentian Diagnostics ASA has allocated a total of 485,000
options to key employees under the existing option program.

The following number of options have been allocated to primary insiders of
Gentian Diagnostics ASA:

Matti Heinonen, Chief Executive Officer: 100,000 options with a strike price of
NOK 60.00 and 100,000 options with a strike price of NOK 44.00. Following the
grant, Mr. Heinonen holds 15,569 shares and 300,000 options in the Company.

Njaal Kind, Group Chief Financial Officer: 50,000 options with a strike price of
NOK 60.00 and 50,000 options with a strike price of NOK 44.00. Following the
allocation Mr. Kind holds 32,194 shares and 240,670 options in the Company.

Aleksandra Havelka, Chief Scientific Officer: 20,000 options with a strike price
of NOK 44.00. Following the allocation Ms. Havelka hold 2,920 shares and 100,000
options in the Company.

Hanne Kristiansen, Vice President Commercial: 20,000 options with a strike price
of NOK 60.00 and 20,000 options with a strike price of NOK 44.00. Following the
allocation Ms. Kristiansen holds 1,023 shares and 40,000 options in the Company.

The right to exercise the options is vested over a period of 2 years, with 50%
of the options vesting by the end of each year as follows: (i) 50% of the
options granted, no earlier than 3 years after the allocation date, (ii) 50% of
the options granted, no earlier than 4 years after the allocation date at an The
options may also be exercised at expiry after 5 years.

Attached are the notifications of the transactions pursuant to the market abuse
regulation article 19. This information is subject to the disclosure
requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

For further information, please contact:
Njaal Kind CFO, Gentian Diagnostics ASA
E-mail: njaal.kind@gentian.no
Phone: +47 919 06 525
gnostics ASA \
E-mail: njaal.kind@gentian.no \
Phone: +47 919 06 525\